A Prospective, Exploratory Study Evaluating the Effectiveness of Treatment Regimens for Locally Advanced/Metastatic Non-resectable Pancreatic Neuroendocrine Tumor (PNET) Guided by in Vitro Drug Sensitivity Testing of Tumor Organoids
The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic neuroendocrine tumors. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response
• Age ≥ 18 and ≤ 75 years old.
• Histologically or cytologically confirmed locally advanced/metastatic Pancreatic Neuroendocrine Tumor
• Surgery was considered impossible or can not receive the radical purpose.
• Able to provide fresh tumor tissue specimens for organoid culture, including: tumor biopsy tissues, tumor surgical specimens, etcy.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.
• Expected survival time≥ six months.
• Patient have been informed and consented, compliance and geographic proximity to ensure adequate follow-up